

APA DSM-V Task Force Member Disclosure Report

Name : William T Carpenter, MD
Job Title : professor and director
Address : PO Box 21247
Catonsville MD 21228-0747
Role : **Member**
Date : **5/2/2011**

Task Force:

Task Force on DSM-V

Biographical Sketch

Biographical Sketch:
William T. Carpenter, Jr., M.D.
Director, Maryland Psychiatric Research Center
Professor of Psychiatry and Pharmacology
University of Maryland School of Medicine
Baltimore, Maryland

William T. Carpenter, Jr., M.D., is a Professor of the University of Maryland School of Medicine and the Director of the Maryland Psychiatric Research Center. He obtained his medical degree from the Wake Forest University School of Medicine. After an internship at the North Carolina Baptist Hospital, he undertook postgraduate training at the University of Rochester Medical Center. He began his research career with the National Institute of Mental Health Intramural Program in 1966, using neuroendocrine strategies to study the psychobiology of affective disorders. He has also been a collaborating investigator with the World Health Organization's International Pilot Study of Schizophrenia. Dr. Carpenter is the Editor-in-Chief for Schizophrenia Bulletin and has served on the editorial boards of the Archives of General Psychiatry, Biological Psychiatry, the Journal of Nervous and Mental Disease, Neuropsychopharmacology, Psychiatry Research, Schizophrenia Bulletin, Schizophrenia Research, Current Psychiatry Reports, and the CD-ROM version of the American College of Neuropsychopharmacology publication Neuropsychopharmacology: Fourth Generation of Progress, and has authored over 350 publications. Dr. Carpenter is a Past-President of the American College of Neuropsychopharmacology and participated in the founding of the National Alliance for Research on Schizophrenia and Depression (NARSAD, The Brain and Behavior Research Fund), and chairs the scientific program committee. Dr. Carpenter's major professional interest has been severe mental illness, especially schizophrenia, including phenomenology of the psychoses, the etiology, pathophysiology, anatomy, and treatment of schizophrenia. He has made original and fundamental contributions in psychopathology, assessment methodology, testing of new treatments, and research ethics. His special professional assignments include service on the NIMH Intramural Research Program Board of Scientific Counselors and as a consultant and reviewer for NIMH and National Institutes of Health on many topics. He chaired the NIMH Research Scientist Career Development Committee and the NIMH National Plan Committee on Treatment Research. Dr. Carpenter has been funded as Principle Investigator for NIMH center grants (CRC, CNS, IRC, ACISR, CIDAR) from 1986 to 2013. He provided expert testimony in the cases of the United States Government v. John Hinckley and in 1989 was a member of the State Department delegation to inspect the political use of psychiatry in the Soviet Union. He has been the recipient of 11 national and international research awards. Dr. Carpenter was elected to the Institute of Medicine of the National Academy of Sciences in 1998.

The table below represents the disclosure for Dr. William T Carpenter, MD of significant interests and affiliations for the three years prior to the DSM Task Force or a DSM Work Group member nomination and the period prior to public announcement of his/her appointment. The table also represents the reported disclosures of significant interests and affiliations for the past full calendar year and the current year to date for Dr. William T Carpenter, MD.

Dr. William T Carpenter, MD has agreed that, from the time of approval through the publication of DSM-V, projected in 2013, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

Commercial or Other Organization	Year(s)	Relationship	Key(s)
AstraZeneca Pharmaceuticals	2004 - 2004	Self	Consultation
AstraZeneca Pharmaceuticals	2006 - 2006	Self	Consultation
Bristol-Myers Squibb	2003 - 2003	Self	Consultation
Atrix Laboratories	2004 - 2004	Self	Consultation
Centron (Solvay/Wyeth)	2007 - 2007	Self	Consultation
Cephalon, Inc.	2007 - 2008	Self	Consultation
Janssen Pharmaceutica	2003 - 2006	Self	Consultation
Johnson & Johnson	2005 - 2005	Self	Consultation
Eli Lilly and Company	2004 - 2004	Self	Consultation
Eli Lilly and Company	2006 - 2006	Self	Consultation
McNeil	2006 - 2006	Self	Consultation
Merck & Co.	2006 - 2006	Self	Consultation
Pfizer Inc.	2005 - 2006	Self	Consultation
Pfizer Inc.	2005 - 2006	Self	Honoraria
Pro Neura Technology	2004 - 2004	Self	Consultation
Saatchi & Saatchi	2004 - 2004	Self	Consultation
Solvay/ Wyeth	2004 - 2007	Self	Consultation
European Regional Patent No: 1487998	2007 - Present	Self	Patents
Teva Pharmaceuticals	2008 - 2008	Self	Consultation
Eli Lilly and Company	2009 - 2009	Self	Consultation
Merck & Co.	2009 - 2009	Self	Consultation
Lundbeck	2010 - 2010	Self	Consultation
Eli Lilly and Company	2010 - 2010	Self	Consultation
Bristol-Myers Squibb	2010 - 2010	Self	Consultation

The table below represents the reported disclosures of uncompensated leadership positions with Non-Profit or Advocacy Organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V for the three years prior to appointment and the current year to date for William T Carpenter, MD.

Non-Profit or Advocacy Organization	Year(s)	Relationship	Role
NARSAD	2003 - Present	Self	Scientific Council
ACNP	2003 - 2009	Self	Fellow: Elected Official
NAMI	2003 - Present	Self	Member, Scientific Council